BRTX
BioRestorative Therapies, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-43.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BRTX vs MDXG vs OSUR vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
MDXG
MiMedx Group, Inc.
Biotechnology
Market Cap$548M
5Y Perf.+2.8%
OSUR
OraSure Technologies, Inc.
Medical - Instruments & Supplies
Market Cap$225M
5Y Perf.-78.5%
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$80M
5Y Perf.-53.7%
BRTX vs MDXG vs OSUR vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BRTX | MDXG | OSUR | XTNT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $2M | $548M | $225M | $80M |
| Revenue (TTM) | $383K | $389M | $85M | $133M |
| Net Income (TTM) | $-13M | $31M | $-53M | $2M |
| Gross Margin | 79.6% | 81.0% | 38.8% | 62.0% |
| Operating Margin | -37.9% | 10.2% | -58.6% | 4.8% |
| Forward P/E | — | 295.2x | — | — |
| Total Debt | $0.00 | $23M | $13M | $35M |
| Cash & Equiv. | $548K | $166M | $199K | $6M |
BRTX vs MDXG vs OSUR vs XTNT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BRTX
MDXG
OSUR
XTNT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BioRestorative Ther… (BRTX) | 100 | 56.3 | -43.8% |
| MiMedx Group, Inc. (MDXG) | 100 | 102.8 | +2.8% |
| OraSure Technologie… (OSUR) | 100 | 21.5 | -78.5% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.3 | -53.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BRTX vs MDXG vs OSUR vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDXG leads in 2 of 6 categories, making it the strongest pick for profitability and margin quality and operational efficiency and capital deployment. BioRestorative Therapies, Inc. is the stronger pick specifically for growth and revenue expansion. OSUR and XTNT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BRTX
BioRestorative Therapies, Inc.
The Growth Play
BRTX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 175.0%, EPS growth 53.0%, 3Y rev CAGR 105.8%
- 175.0% revenue growth vs OSUR's -38.1%
Best for: growth exposure
MDXG
MiMedx Group, Inc.
The Long-Run Compounder
MDXG carries the broadest edge in this set and is the clearest fit for long-term compounding and defensive.
- -48.5% 10Y total return vs OSUR's -53.1%
- Beta 1.22, current ratio 4.32x
- 7.9% margin vs BRTX's -33.0%
- 9.7% ROA vs BRTX's -224.5%, ROIC 42.3% vs -100.4%
Best for: long-term compounding and defensive
OSUR
OraSure Technologies, Inc.
The Defensive Pick
OSUR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.45, Low D/E 3.9%, current ratio 6.58x
- +12.2% vs BRTX's -87.5%
Best for: sleep-well-at-night
XTNT
Xtant Medical Holdings, Inc.
The Income Pick
XTNT is the clearest fit if your priority is income & stability.
- beta 0.69
- Beta 0.69 vs BRTX's 2.21
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BRTX | 175.0% revenue growth vs OSUR's -38.1% |
| Quality / Margins | MDXG | 7.9% margin vs BRTX's -33.0% |
| Stability / Safety | XTNT | Beta 0.69 vs BRTX's 2.21 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | OSUR | +12.2% vs BRTX's -87.5% |
| Efficiency (ROA) | MDXG | 9.7% ROA vs BRTX's -224.5%, ROIC 42.3% vs -100.4% |
BRTX vs MDXG vs OSUR vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2025
FY 2024
BRTX vs MDXG vs OSUR vs XTNT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMDXGLAGGINGOSUR
Who Leads Where
MDXG leads in 2 of 6 categories
XTNT leads 1 • BRTX leads 0 • OSUR leads 0 • 2 tied
Explore the data ↓OSUROraSure Technologies,…
0leads
BRTXBioRestorative Therap…
0leads
XTNTXtant Medical Holding…
1leads
MDXGMiMedx Group, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs XTNTvs BRTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MDXG4/6
Valuation MetricsMultiples, price ratios, and targets
XTNT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MDXG7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MDXG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDXG is the larger business by revenue, generating $389M annually — 1015.7x BRTX's $383,400. MDXG is the more profitable business, keeping 7.9% of every revenue dollar as net income compared to BRTX's -33.0%. On growth, XTNT holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $383,400 | $389M | $85M | $133M |
| EBITDAEarnings before interest/tax | -$14M | $53M | -$45M | $11M |
| Net IncomeAfter-tax profit | -$13M | $31M | -$53M | $2M |
| Free Cash FlowCash after capex | -$11M | $66M | -$33M | $5M |
| Gross MarginGross profit ÷ Revenue | +79.6% | +81.0% | +38.8% | +62.0% |
| Operating MarginEBIT ÷ Revenue | -37.9% | +10.2% | -58.6% | +4.8% |
| Net MarginNet income ÷ Revenue | -33.0% | +7.9% | -61.9% | +1.3% |
| FCF MarginFCF ÷ Revenue | -28.1% | +17.0% | -38.9% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -94.9% | -33.1% | -99.9% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -153.8% | -2.4% | -52.4% | +123.7% |
MDXG leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
XTNT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| Market CapShares × price | $2M | $548M | $225M | $80M |
| Enterprise ValueMkt cap + debt − cash | $1M | $405M | $238M | $109M |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | 11.53x | -3.33x | -4.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 295.20x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 5.14x | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.48x | 1.31x | 1.96x | 0.68x |
| Price / BookPrice ÷ Book value/share | 0.20x | 2.15x | 0.67x | 1.77x |
| Price / FCFMarket cap ÷ FCF | — | 7.51x | — | — |
XTNT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
MDXG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-6 for BRTX. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XTNT's 0.82x. On the Piotroski fundamental quality scale (0–9), MDXG scores 5/9 vs XTNT's 2/9, reflecting solid financial health.
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.7% | +12.9% | -15.1% | +3.8% |
| ROA (TTM)Return on assets | -2.2% | +9.7% | -12.8% | +1.8% |
| ROICReturn on invested capital | -100.4% | +42.3% | -20.0% | -12.8% |
| ROCEReturn on capital employed | -124.7% | +25.7% | -16.8% | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.09x | 0.04x | 0.82x |
| Net DebtTotal debt minus cash | -$547,890 | -$144M | $13M | $29M |
| Cash & Equiv.Liquid assets | $547,890 | $166M | $199,278 | $6M |
| Total DebtShort + long-term debt | $0 | $23M | $13M | $35M |
| Interest CoverageEBIT ÷ Interest expense | — | 25.32x | — | 1.55x |
MDXG leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — MDXG and OSUR and XTNT each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDXG five years ago would be worth $3,712 today (with dividends reinvested), compared to $64 for BRTX. Over the past 12 months, OSUR leads with a +12.2% total return vs BRTX's -87.5%. The 3-year compound annual growth rate (CAGR) favors XTNT at -4.3% vs BRTX's -64.9% — a key indicator of consistent wealth creation.
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -81.6% | -43.1% | +31.5% | -24.0% |
| 1-Year ReturnPast 12 months | -87.5% | -47.1% | +12.2% | +10.0% |
| 3-Year ReturnCumulative with dividends | -95.7% | -36.6% | -55.2% | -12.3% |
| 5-Year ReturnCumulative with dividends | -99.4% | -62.9% | -68.3% | -66.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -48.5% | -53.1% | -97.8% |
| CAGR (3Y)Annualised 3-year return | -64.9% | -14.1% | -23.5% | -4.3% |
Evenly matched — MDXG and OSUR and XTNT each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OSUR and XTNT each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than BRTX's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSUR currently trades 81.9% from its 52-week high vs BRTX's 11.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.21x | 1.22x | 1.45x | 0.69x |
| 52-Week HighHighest price in past year | $2.05 | $7.99 | $3.82 | $0.95 |
| 52-Week LowLowest price in past year | $0.19 | $3.02 | $2.08 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +11.0% | +46.2% | +81.9% | +60.0% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 49.3 | 47.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 5.4M | 1.4M | 473K | 142K |
Evenly matched — OSUR and XTNT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MDXG as "Buy", OSUR as "Hold". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs 27.8% for OSUR (target: $4).
| Metric | BRTXBioRestorative Th… | MDXGMiMedx Group, Inc. | OSUROraSure Technolog… | XTNTXtant Medical Hol… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | — |
| Price TargetConsensus 12-month target | — | $10.00 | $4.00 | — |
| # AnalystsCovering analysts | — | 15 | 13 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 2 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.6% | +6.7% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MDXG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTNT leads in 1 (Valuation Metrics). 2 tied.
Best OverallMiMedx Group, Inc. (MDXG)Leads 2 of 6 categories
Loading custom metrics...
BRTX vs MDXG vs OSUR vs XTNT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is BRTX or MDXG or OSUR or XTNT a better buy right now?
For growth investors, BioRestorative Therapies, Inc.
(BRTX) is the stronger pick with 175. 0% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BRTX or MDXG or OSUR or XTNT?
Over the past 5 years, MiMedx Group, Inc.
(MDXG) delivered a total return of -62. 9%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: MDXG returned -48. 5% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BRTX or MDXG or OSUR or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus BioRestorative Therapies, Inc. 's 2. 21β — meaning BRTX is approximately 220% more volatile than XTNT relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 82% for Xtant Medical Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BRTX or MDXG or OSUR or XTNT?
By revenue growth (latest reported year), BioRestorative Therapies, Inc.
(BRTX) is pulling ahead at 175. 0% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: BioRestorative Therapies, Inc. grew EPS 53. 0% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, BRTX leads at 105. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BRTX or MDXG or OSUR or XTNT?
MiMedx Group, Inc.
(MDXG) is the more profitable company, earning 11. 6% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BRTX or MDXG or OSUR or XTNT more undervalued right now?
Analyst consensus price targets imply the most upside for MDXG: 171.
0% to $10. 00.
07Which pays a better dividend — BRTX or MDXG or OSUR or XTNT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BRTX or MDXG or OSUR or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTNT: -97. 8%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BRTX and MDXG and OSUR and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BRTX is a small-cap high-growth stock; MDXG is a small-cap high-growth stock; OSUR is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(BRTX: -94.9% · MDXG: -33.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.